Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Sponsor: Wockhardt
Terminated
Business reasons
Other Type I Diabetes trials with similar outcome
Listed as NCT01308437, this PHASE3 trial focuses on Type I Diabetes and remains terminated or withdrawn. Sponsored by Wockhardt, it has been updated 8 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jul 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2023 [monthly]
Terminated PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Wockhardt
For direct contact, visit the study record on ClinicalTrials.gov .